A randomised clinical trial to assess the effect of total enteral and total parenteral nutritional support on metabolic, inflammatory and oxidative markers in patients with predicted severe acute pancreatitis (APACHE II >= 66)

Background: Total enteral nutrition (TEN) within 48 h of admission has recently been shown to be safe and efficacious as part of the management of severe acute pancreatitis. Our aim was to ascertain the safety of immediate TEN in these patients and the effect of TEN on systemic inflammation, psychological state, oxidative stress, plasma glutamine levels and endotoxaemia. Methods: Patients admitted with predicted severe acute pancreatitis (APACHE II score 15) were randomised to total enteral (TEN; n = 8) or total parenteral nutrition (TPN; n = 9). Measurements of systemic inflammation (C-reactive protein), fatigue ( visual analogue scale), oxidative stress ( plasma thiobarbituric acid- reactive substances), plasma glutamine and anti-endotoxin IgG and IgM antibody concentrations were made on admission and repeated on days 3 and 7 thereafter. Clinical progress was monitored using APACHE II score. Organ failure and complications were recorded. Results: All patients tolerated the feeding regime well with few nutrition-related complications. Fatigue improved in both groups but more rapidly in the TEN group. Oxidative stress was high on admission and rose by similar amounts in both groups. Plasma glutamine concentrations did not change significantly in either group. In the TPN group, 3 patients developed respiratory failure and 3 developed non-respiratory single organ failure. There were no such complications in the TEN group. Hospital stay was shorter in the TEN group [ 7 (4-14) vs. 10 (7-26) days; p = 0.05] as was time to passing flatus and time to opening bowels [1 (0-2) vs. 2 (1-5) days; p = 0.01]. The cost of TEN was considerably less than of TPN. Conclusion: Immediate institution of nutritional support in the form of TEN is safe in predicted severe acute pancreatitis. It is as safe and as efficacious as TPN and may be beneficial in the clinical course of this disease. Copyright (C) 2003 S. Karger AG, Basel and IAP.

Modelo experimental de lesões intra-epiteliais e de adenocarcinoma ductal pancreático induzidos por 7,12-dimetilbenzantraceno em camundongos

INTRODUÇÃO: O adenocarcinoma de pâncreas apresenta um mau prognóstico. A utilização de modelos experimentais é necessária para a compreensão do comportamento biológico tumoral, principalmente das lesões precoces (neoplasias intra-epiteliais pancreáticas - NIPan) e para o desenvolvimento de opções terapêuticas. OBJETIVO: Avaliar a carcinogênese pancreática induzida por 7,12-dimetilbenzantraceno (DMBA), em camundongos, aplicando a classificação das neoplasias intra-epiteliais pancreáticas. MÉTODOS: 90 camundongos machos, mus musculus, da cepa CF1, foram submetidos à laparotomia mediana e 1 mg de DMBA foi implantado na porção cefálica do pâncreas. Os animais foram divididos em dois grupos, com eutanásia em 30 e 60 dias. Em seguida, o pâncreas foi retirado, fixado em formalina e foram confeccionadas lâminas coradas com hematoxilina eosina. Os cortes histológicos foram avaliados por dois patologistas de acordo com os seguintes critérios: pâncreas normal, hiperplasia reacional, NIPan 1A, NIPan 1B, NIPan 2, NIPan 3 e carcinoma. As alterações inflamatórias também foram analisadas. RESULTADOS: A avaliação patológica evidenciou, no grupo de 30 dias: 4 (16,7%) animais com hiperplasia reativa, 16 (66,6%) com NIPan e 4 (16,7%) com adenocarcinoma. No grupo de 60 dias: 10 (27,1%) animais com hiperplasia reativa, 13 (35,1%) com NIPan e 14 (37,8%) com adenocarcinoma. A diferença entre os grupos apresentou significância estatistística (P < 0,05 – teste exato de Fisher). A prevalência de alterações inflamatórias em 30 dias foi: pancreatite aguda (n=11), pancreatite crônica (n=5) e inflamação dependente da bolsa (n=8). No grupo de 60 dias 11 espécimes apresentavam pancreatite aguda e 26 pancreatite crônica. CONCLUSÕES: O modelo experimental com DMBA em camundongos, induz neoplasia intra-epitelial pancreática e adenocarcinoma ductal histologicamente semelhantes ao carcinoma pancreático em humanos. Este modelo pode ser utilizado na investigação da carcinogênese com enfoque na progressão molecular das lesões precursoras até o adenocarcinoma.

Avaliação dos efeitos do álcool e da cafeína em modelo de carcinogênese pancreática induzida por 7,12 dimetilbenzentraceno (DMBA) em camundongos

Introdução: Modelos experimentais de indução da carcinogênese pancreática são necessários para melhor compreensão da biologia tumoral e para estudar os efeitos de agentes promotores ou protetores. Objetivos: Avaliar os efeitos do álcool e da cafeína na carcinogênese pancreática induzida pelo 7,12- dimetilbenzantraceno (DMBA), aplicando a classificação sistematizada de neoplasias intra-epitelias pancreáticas (PanIN) de Hruban e cols. (2001)(1) em camundongos. Métodos: Cento e vinte camundongos mus musculus, machos, adultos foram divididos em quatro grupos. Em todos os animais foi induzida a carcinogênese pancreática pela implantação de 1mg de DMBA no pâncreas dos animais. Os animais recebiam ou água ou cafeína ou álcool ou álcool+cafeína de acordo com seu grupo. Para a análise histológica do pâncreas, adotou-se a classificação sistematizada das lesões precursoras (PanIN). Resultados: No grupo água + DMBA, 16,6% dos animais desenvolveram adenocarcinoma ductal pancreático (ADP) e 66,6% apresentaram neoplasias intra-epiteliais pancreáticas (PanIN). No grupo álcool + DMBA, 52,9% desenvolveram ADP (p<0,05) e 35,3% PanIN. No grupo cafeína + DMBA, 15% apresentaram ADP e 65% PanIN. No grupo álcool+cafeína + DMBA, 23,8% desenvolveram ADP e 71,4% PanIN. Conclusões: O modelo experimental de carcinogênese pancreática em camundongos utilizando o DMBA, é eficaz na indução de lesões precursoras e de adenocarcinoma pancreático. O álcool está associado ao aumento da freqüência de adenocarcinoma pancreático, enquanto que a cafeína não demonstrou este efeito.

Avaliação imuno-histoquímica das galectinas -1, -3 e -7 em displasia epitelial ora

Introdução: A displasia epitelial oral (DEO) é uma lesão potencialmente maligna, cujo diagnóstico e gradação se baseia na histologia das alterações arquiteturais e citológicas, preconizados pela OMS, que divide a lesão em leve, moderada e severa, o qual é subjetivo. Maior concordância é observada no uso do sistema binário (baixo/alto risco), o qual está relacionado ao risco de transformação maligna. As galectinas constituem uma família de lectinas e estão envolvidas na tumorigênese, sendo a -1, -3 e -7 as mais investigadas, devido a expressão alterada em cânceres orais. Materiais e métodos: Foi analisada a expressão imuno-histoquímica dessas proteínas em 50 espécimes de DEO (21 baixo/ 29 alto risco) e 5 de mucosa oral normal e relacionamos com a presença/ausência de marcação, padrão de distribuição, intensidade, localização epitelial (estratificação) (1/3 inferior, médio e superior), e localização celular (compartimento) (núcleo, citoplasma e membrana) . Resultados: Dos 29 casos de alto e dos 21 de baixo risco, 21 (72,4%) e 12 (57,1%) foram positivos para a galectina -1, respectivamente. Dessa forma, de 50 casos, 33 foram positivos. O núcleo e citoplasma foram positivos em 91,7% nas de baixo risco e em 90,5% nas de alto. Todos os casos de mucosa normal foram negativos. Com relação a galectina -3, dos 21 casos das DEOs de baixo risco, 12 (57,1%) apresentaram expressão e dos 29 casos das DEOs de alto risco, 15 (51,7%) foram positivos, havendo imunoexpressão em um total de 27 casos. O padrão difuso, assim como a fraca intensidade foram os mais freqüentes para os 2 graus. O núcleo e o citoplasma foram a localização mais comum tanto nas lesões de baixo (58,3%), quanto nas de alto risco (66,7%). Quatro casos de mucosa normal foram positivos, com marcação membranar e intensidade fraca. Dos 21 casos das DEOs de baixo risco, 17 (81%) apresentaram expressão imuno-histoquímica para a galectina -7 e das 29 DEOs de alto risco, 27 (93,1%) foram positivos. Então, a expressão imuno-histoquímica da galectina -7 foi observada em 44 casos, a maioria com intensidade de moderada a forte. O núcleo e o citoplasma foram a localização mais freqüente, nas de baixo (70,6%) e alto risco (66,7%). Quatro espécimes de mucosa normal marcaram membrana em terço médio e superior, com intensidade moderada a forte. Conclusões: Alterações na expressão das galectinas -3 e -7 e principalmente da -1 sugerem seu envolvimento na fisiopatologia das displasias, participando do processo de transformação de fenótipo normal para o displásico.

Transverse-Momentum and Pseudorapidity Distributions of Charged Hadrons in pp Collisions at root s=7 TeV

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Análise do imprinting e da expressão dos genes H19 e IGF2 em células de Sertoli humanas apos exposição in vitro ao 2,3,7,8-Tetraclorodibenzo-p-dioxina (TCDD)

Pós-graduação em Biologia Geral e Aplicada - IBB

Cumulative long-term safety, efficacy and patient-reported outcomes in children with juvenile idiopathic arthritis treated with intravenous abatacept: up to 7 years of treatment

The long-term efficacy and safety of intravenous abatacept in patients (pts) with juvenile idiopathic arthritis (JIA) have been reported previously from the Phase III AWAKEN trial ([1, 2]). Here, we report efficacy, safety and pt-reported outcomes from the open-label, long-term extension (LTE) of AWAKEN, with up to 7 years of follow-up. Pts entered the LTE if they were JIA ACR 30 non-responders (NR) at the end of the 4-month lead-in period (abatacept only), or if they received abatacept or placebo (pbo) in the 6-month double-blind (DB) period. The Child Health Questionnaire was used to evaluate health-related quality of life (HRQoL); physical (PhS) and psychosocial (PsS) summary and pain scores were analyzed. Pain was assessed by parent global assessment using a 100 mm visual analog scale. Efficacy and HRQoL evaluations are reported up to Day 1765 (~ Year 5.5). Safety is presented for the cumulative period (lead-in, DB and LTE), for all pts who received abatacept during the LTE. Of the 153 pts entering the LTE (58 from DB abatacept group, 59 from DB pbo group, 36 NR), 69 completed the trial (29 abatacept, 27 pbo, 13 NR). For pts treated in the LTE, mean (range) exposure to abatacept was 53.6 (5.6–85.6) months. During the LTE, incidence rates of AEs and serious AEs per 100 pt-years were 209.1 and 5.6. Thirty pts (19.6%) had serious AEs; most were unrelated and were musculoskeletal (8.5%) or infectious events (6.5%). No malignancy was reported. There was one death (accidental; unrelated). At Day 169, JIA ACR 50 and 70 response rates were 79.3% and 55.2% in the abatacept group, and 52.5% and 30.5% in the pbo group; 31.0% and 10.2% of pts in the abatacept and pbo groups, respectively, had inactive disease. By Day 1765, JIA ACR 50 and 70 response rates were 93.9% and 78.8% in the abatacept group, and 80.0% and 63.3% in the pbo group; 51.5% and 33.3% had inactive disease. In the NR group, 69.2% and 53.8% of pts achieved JIA ACR 50 and 70 responses at Day 1765, and 30.8% had inactive disease. In pts who entered the LTE, mean baseline PhS scores were below the range for healthy children (abatacept 30.2, pbo 31.0, NR 29.5). At Day 169, 38.3% of pts had reached a PhS score >50 ((1). By the end of the LTE, 43.5% of pts had reached a PhS score >50. At baseline, mean PsS scores for those who entered the LTE were slightly lower than the mean for healthy children (abatacept 43.5, pbo 44.2, NR 47.0). At Day 169, 54.9% of pts had a PsS score >50 (1). By Day 1765, 58.1% of pts had reached a PsS score >50. At baseline, the mean pain score was 42.9. By Day 169, 13.9% of pts were considered pain free (pain score = 0); this was maintained over the LTE (1).

Measurement of ℤℤ production in pp collisions at sqrts=7 TeV and limits on anomalous ℤℤℤ ℤℤgamma couplings with the ATLAS detector

A measurement of the ZZ production cross section in proton-proton collisions at root s = 7 TeV using data recorded by the ATLAS experiment at the Large Hadron Collider is presented. In a data sample corresponding to an integrated luminosity of 4.6 fb(-1) collected in 2011, events are selected that are consistent either with two Z bosons decaying to electrons or muons or with one Z boson decaying to electrons or muons and a second Z boson decaying to neutrinos. The ZZ((*)) -> l(+)l(-)l'(+)l'(-) and ZZ -> l(+)l(-) nu(nu) over bar cross sections are measured in restricted phase-space regions. These results are then used to derive the total cross section for ZZ events produced with both Z bosons in the mass range 66 to 116 GeV, sigma(tot)(ZZ) = 6.7 +/- 0.7 (stat.) (+0.4)(-0.3) (syst.) +/- 0.3 (lumi.) pb, which is consistent with the Standard Model prediction of 5.89(-0.18)(+0.22) pb calculated at next-to-leading order in QCD. The normalized differential cross sections in bins of various kinematic variables are presented. Finally, the differential event yield as a function of the transverse momentum of the leading Z boson is used to set limits on anomalous neutral triple gauge boson couplings in ZZ production.

Measurement of the low-mass Drell-Yan differential cross section at √8 = 7 TeV using the ATLAS detector

The differential cross section for the process Z/√ → ℓℓ (ℓ = e, μ) as a function of dilepton invariant mass is measured in pp collisions at ps = 7TeV at the LHC using the ATLAS detector. The measurement is performed in the e and μ channels for invariant masses between 26 GeV and 66 GeV using an integrated luminosity of 1.6 fb−1 collected in 2011 and these measurements are combined. The analysis is extended to invariant masses as low as 12 GeV in the muon channel using 35 pb−1 of data collected in 2010. The cross sections are determined within fiducial acceptance regions and corrections to extrapolate the measurements to the full kinematic range are provided. Next-to-next-to-leading-order QCD predictions provide a significantly better description of the results than next-to-leadingorder QCD calculations, unless the latter are matched to a parton shower calculation.

The differential production cross section of the phi (1020) meson in sqrts = 7 TeV pp collisions measured with the ATLAS detector

Ameasurement is presented of the φ×BR(φ → K+K−) production cross section at √s = 7 TeV using pp collision data corresponding to an integrated luminosity of 383 μb−1, collected with theATLAS experiment at the LHC. Selection of φ(1020) mesons is based on the identification of charged kaons by their energy loss in the pixel detector. The differential cross section ismeasured as a function of the transverse momentum, pT,φ , and rapidity, yφ, of the φ(1020) meson in the fiducial region 500< pT,φ <1200MeV, |yφ| < 0.8, kaon pT,K > 230 MeV and kaon momentum pK < 800 MeV. The integrated φ(1020)-meson production cross section in this fiducial range is measured to be σφ×BR(φ → K+K−) = 570 ± 8 (stat) ± 66 (syst) ± 20 (lumi) μb.

Na 1 Nachlass Max Horkheimer, 660 - Berichte über die Arbeit des Instituts für Sozialforschung u.a. (p. IX 66-IX 77)

"American Jewish Committee. Progress Report of the Scientific Department" (22.6.1945), a) als Typoskript vervielfältigt, 27 Blatt, b) Typoskript, 28 Blatt; "Über Geschichte und Tätigkeiten des Instituts für Sozialforschung", Interview Leo Löwenthal - David Berger gesendet am 29.10.1947 (?) von Radio Newsreel, USA, deutsche Übersetzung, als Typoskript vervielfältigt, mit handschriftlichen Korrekturen, 19 Blatt; "Papers Regarding the Institute of Social Research" (August 1948), Abschriften aus verschiedenen Berichten und Briefen, Typoskript, 14 Blatt; P. Hübner: "Soziologie im Kampf gegen das Vorurteil. HICOG fördert Institut für Sozialforschung an Frankfurts Universität", veröffentlicht in: Neue Zeitung, Frankfurt (1950), Typoskript mit handschriftlichen Korrekturen von Max Horkheimer, 3 Blatt; Theodor W. Adorno: "Plans of New Research Projects of the 'Institut für Sozialforschung'" (November 1950), Typoskript, 7 Blatt; "Memorandum über das Institut für Sozialforschung an der Universität Frankfurt/Main" (November 1950), a)-d) deutsche Fassung, 41 Blatt (mit Anlagen); e)-f) englische Fassung, 25 Blatt (mit Anlagen); "The Institute for Social Research, Oslo, Norway" (1950), Drucksache, 2 Blatt; "Report for UNESCO, Paris", Über das Institut für Sozialforschung (5.4. 1951), a) englische Fassung, Typoskript, 3 Blatt, b) deutscher Entwurf, Typoskript, 3 Blatt; Institut zur Förderung öffentlicher Angelegenheiten e.V., Frankfurt am Main: "3 Rundschreiben. Betreff: Clearingstelle zur Meinungsforschung (empirische Sozialforschung), Materialien zur Meinungsforschung, Institut für Sozialforschung an der Johann-Wolfgang Goethe-Universität in Frankfurt am Main" (16.4.1951), als Typoskript vervielfältigt, 4 Blatt; "Progress Report on the Institute of Social Research's Work at Frankfurt University" (10.2.1951), als Typoskript vervielfältigt, 2 Blatt; "Bericht über Geschichte und Tätigkeit des Instituts für Sozialforschung an der Johann Wolfgang Goethe-Universität, Frankfurt am Main" (1.7.1951), a) Typoskript, 3 Blatt, b) als Entwurf für ein Rundschreiben von Friedrich Pollock, Typoskript, 4 Blatt; Angaben über das Institut für Sozialforschung, Frankfurt, Antworten für einen Fragebogen (September 1951), Typoskript, 2 Blatt; "Memorandum über Arbeiten und die Organisation des Instituts" (Mai 1953), Typoskript, 4 Blatt;